STRATA Skin Sciences Inc (SSKN) - Net Assets
Based on the latest financial reports, STRATA Skin Sciences Inc (SSKN) has net assets worth $2.91 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.52 Million) and total liabilities ($27.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of STRATA Skin Sciences Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.91 Million |
| % of Total Assets | 9.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -88.56% |
| 10-Year Change | -80.24% |
| Growth Volatility | 39.28 |
STRATA Skin Sciences Inc - Net Assets Trend (2002–2025)
This chart illustrates how STRATA Skin Sciences Inc's net assets have evolved over time, based on quarterly financial data. See SSKN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for STRATA Skin Sciences Inc (2002–2025)
The table below shows the annual net assets of STRATA Skin Sciences Inc from 2002 to 2025. For live valuation and market cap data, see SSKN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.91 Million | -41.51% |
| 2024-12-31 | $4.97 Million | -60.81% |
| 2023-12-31 | $12.69 Million | -41.88% |
| 2022-12-31 | $21.83 Million | -14.10% |
| 2021-12-31 | $25.41 Million | -1.85% |
| 2020-12-31 | $25.89 Million | -9.64% |
| 2019-12-31 | $28.65 Million | -8.30% |
| 2018-12-31 | $31.25 Million | +40.47% |
| 2017-12-31 | $22.25 Million | +51.13% |
| 2016-12-31 | $14.72 Million | -8.50% |
| 2015-12-31 | $16.09 Million | +31.04% |
| 2014-12-31 | $12.28 Million | +47.97% |
| 2013-12-31 | $8.30 Million | -40.64% |
| 2012-12-31 | $13.98 Million | -53.11% |
| 2011-12-31 | $29.81 Million | -6.26% |
| 2010-12-31 | $31.80 Million | +4.89% |
| 2009-12-31 | $30.32 Million | +100.91% |
| 2008-12-31 | $15.09 Million | -27.36% |
| 2007-12-31 | $20.77 Million | -2.54% |
| 2006-12-31 | $21.31 Million | +16.79% |
| 2005-12-31 | $18.25 Million | +614.06% |
| 2004-12-31 | $-3.55 Million | -1528.46% |
| 2003-12-31 | $-218.00K | +95.32% |
| 2002-12-31 | $-4.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to STRATA Skin Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25025700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.21% |
| Other Components | $257.31 Million | 8848.25% |
| Total Equity | $2.91 Million | 100.00% |
STRATA Skin Sciences Inc Competitors by Market Cap
The table below lists competitors of STRATA Skin Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Greencastle Resources Ltd.
V:VGN
|
$879.11K |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
$882.96K |
|
GenixPharmaceucticals Corporation
V:GENX
|
$885.77K |
|
NeutriSci International Inc
V:NU
|
$892.12K |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
$868.39K |
|
CENTAURUS ENERGY INC.
F:72M0
|
$867.56K |
|
Michelmersh Brick Holdings Plc
LSE:MBH
|
$865.91K |
|
Geiger Counter Limited
LSE:GCL
|
$864.82K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STRATA Skin Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,972,000 to 2,908,000, a change of -2,064,000 (-41.5%).
- Net loss of 6,261,000 reduced equity.
- New share issuances of 3,579,000 increased equity.
- Other factors increased equity by 618,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.26 Million | -215.3% |
| Share Issuances | $3.58 Million | +123.07% |
| Other Changes | $618.00K | +21.25% |
| Total Change | $- | -41.51% |
Book Value vs Market Value Analysis
This analysis compares STRATA Skin Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-135.60 | $0.15 | x |
| 2001-12-31 | $-111.03 | $0.15 | x |
| 2002-12-31 | $-151.72 | $0.15 | x |
| 2003-12-31 | $-6.75 | $0.15 | x |
| 2004-12-31 | $-100.48 | $0.15 | x |
| 2005-12-31 | $260.05 | $0.15 | x |
| 2006-12-31 | $94.36 | $0.15 | x |
| 2007-12-31 | $73.03 | $0.15 | x |
| 2008-12-31 | $46.34 | $0.15 | x |
| 2009-12-31 | $78.56 | $0.15 | x |
| 2010-12-31 | $66.13 | $0.15 | x |
| 2011-12-31 | $58.64 | $0.15 | x |
| 2012-12-31 | $22.71 | $0.15 | x |
| 2013-12-31 | $16.96 | $0.15 | x |
| 2014-12-31 | $11.59 | $0.15 | x |
| 2015-12-31 | $94.22 | $0.15 | x |
| 2016-12-31 | $6.36 | $0.15 | x |
| 2017-12-31 | $3.37 | $0.15 | x |
| 2018-12-31 | $1.04 | $0.15 | x |
| 2019-12-31 | $0.90 | $0.15 | x |
| 2020-12-31 | $0.77 | $0.15 | x |
| 2021-12-31 | $0.75 | $0.15 | x |
| 2022-12-31 | $0.63 | $0.15 | x |
| 2023-12-31 | $0.36 | $0.15 | x |
| 2024-12-31 | $0.13 | $0.15 | x |
| 2025-12-31 | $0.06 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STRATA Skin Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -215.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.40%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 10.50x
- Recent ROE (-215.30%) is below the historical average (-74.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -1085.71% | 0.06x | 0.00x | $-1.87 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.53 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-675.30K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.93 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.26 Million |
| 2005 | -36.86% | 0.00% | 0.00x | 1.05x | $-8.55 Million |
| 2006 | -49.69% | 0.00% | 0.00x | 1.05x | $-12.72 Million |
| 2007 | -57.47% | 0.00% | 0.00x | 1.06x | $-14.01 Million |
| 2008 | -116.67% | -176050.31% | 0.00x | 1.10x | $-19.11 Million |
| 2009 | -60.87% | 0.00% | 0.00x | 1.06x | $-21.48 Million |
| 2010 | -62.65% | 0.00% | 0.00x | 1.06x | $-23.10 Million |
| 2011 | -68.39% | 0.00% | 0.00x | 1.05x | $-23.37 Million |
| 2012 | -162.24% | -8142.25% | 0.02x | 1.24x | $-24.07 Million |
| 2013 | -312.78% | -4841.04% | 0.04x | 1.70x | $-26.78 Million |
| 2014 | -130.60% | -1752.13% | 0.05x | 1.63x | $-17.26 Million |
| 2015 | -173.49% | -150.90% | 0.36x | 3.19x | $-29.52 Million |
| 2016 | -22.66% | -10.50% | 0.74x | 2.93x | $-4.81 Million |
| 2017 | -96.71% | -68.41% | 0.81x | 1.74x | $-23.74 Million |
| 2018 | -12.91% | -13.51% | 0.63x | 1.52x | $-7.16 Million |
| 2019 | -13.23% | -12.00% | 0.67x | 1.65x | $-6.66 Million |
| 2020 | -17.04% | -19.11% | 0.49x | 1.81x | $-7.00 Million |
| 2021 | -10.65% | -9.03% | 0.64x | 1.83x | $-5.25 Million |
| 2022 | -25.42% | -15.35% | 0.69x | 2.39x | $-7.73 Million |
| 2023 | -85.36% | -32.47% | 0.79x | 3.31x | $-12.10 Million |
| 2024 | -202.86% | -30.05% | 0.93x | 7.27x | $-10.58 Million |
| 2025 | -215.30% | -20.40% | 1.01x | 10.50x | $-6.55 Million |
Industry Comparison
This section compares STRATA Skin Sciences Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STRATA Skin Sciences Inc (SSKN) | $2.91 Million | 0.00% | 9.50x | $877.34K |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About STRATA Skin Sciences Inc
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer … Read more